Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
about
A lymphomagenic role for HIV beyond immune suppression?HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.Biomarkers of HIV-associated Cancer.Burkitt's lymphoma mimicking EBV disease as first sign of vertical HIV infection in an adolescent.Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden.Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDSCumulative HIV viremia and non-AIDS-defining malignancies among a sample of HIV-infected male veteransEarly development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitutionCancer biomarkers in HIV patientsImmunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era.Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.Viral load monitoring and antiretroviral treatment outcomes in a pediatric HIV cohort in GhanaHIV-induced immune activation: pathogenesis and clinical relevance - summary of a workshop organized by the German AIDS Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008Clinical presentation, treatment, and outcomes among 65 patients with HIV-associated lymphoma treated at the University of North Carolina, 2000-2010The Effects of Viral Load Burden on Pregnancy Loss among HIV-Infected Women in the United States.Cancer prevention in HIV-infected populations.Cardiac effects in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents: a view from the United States of America.Reevaluating Cumulative HIV-1 Viral Load as a Prognostic Predictor: Predicting Opportunistic Infection Incidence and Mortality in a Ugandan Cohort.Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era.Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death.High cancer-related mortality in an urban, predominantly African-American, HIV-infected populationExpression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice.Impact of the HIV epidemic and Anti-Retroviral Treatment policy on lymphoma incidence and subtypes seen in the Western Cape of South Africa, 2002-2009: preliminary findings of the Tygerberg Lymphoma Study Group.Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy.HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.A review of the role of lymphoma markers and occupational and environmental exposures.Combination antiretroviral therapy and cancer risk.Virologic and Immunologic Outcomes in HIV-Infected Patients with Cancer.Human gammaherpesviruses viraemia in HIV infected patients.Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis.The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people.Durable Viral Suppression and Transmission Risk Potential Among Persons With Diagnosed HIV Infection: United States, 2012-2013.Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada.HIV-associated lymphoma sub-type distribution, immunophenotypes and survival in an urban clinic population.Patterns of HIV viremia and viral suppression before diagnosis of non-AIDS-defining cancers in HIV-infected individuals.Viral etiology, clinical and laboratory features of adult hemophagocytic lymphohistiocytosis.Epstein-Barr and cytomegalovirus DNA salivary shedding correlate with long-term plasma HIV RNA detection in HIV-infected men who have sex with men.Hodgkin lymphoma is as common as non-Hodgkin lymphoma in HIV-positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study.Combining CD4 recovery and CD4: CD8 ratio restoration as an indicator for evaluating the outcome of continued antiretroviral therapy: an observational cohort study.Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
P2860
Q26771672-F108B9C7-2572-4C7F-B3E5-5CC5EB5958F4Q33598231-821C3BF6-F870-4258-8968-C9106F7003AAQ33856851-2FE530D5-4039-41D2-8D19-30DFFC1D344DQ33864028-C9B980C5-AEC9-4322-8CFF-42C72A3E8E2AQ33883560-1998042F-5FE8-4F0A-9033-40A1ED67300BQ33916321-FC06C4B1-7A20-46CC-AC77-88F6DC03B32CQ34173349-82102CE5-115F-4DEB-BD06-3BDA5A522323Q34498993-9532D231-9459-4EB3-AC81-62CDBDE508DFQ34661370-79B91CD9-5599-40E9-85E8-56902C6C0D23Q34806379-C2CD324D-F6A4-45C7-8401-2E90BCDD6CF1Q35290298-BB406166-0BAE-4DE1-A6D3-60E5C554DD5BQ35914071-11D9E3BD-573D-41AB-ABE8-48850A45F042Q35958548-45DBA7C7-CB4A-4309-9EAC-3C3753D65975Q36102589-B68B9299-1B52-4FD9-B212-F5B833C3E6D6Q36259895-11C3241F-DBDD-4378-A490-67AF80323696Q36680086-E333A9D1-B379-4BA4-A2C3-A6A4BAD4E628Q36941650-61270903-A568-485E-B522-65AD326B5041Q37056879-DE28684E-5E9A-4171-980B-F0D04677FAEAQ37106782-EBAF5468-2F0B-41B5-A5A1-E390654064E9Q37167877-A6337F2D-2E54-410E-805E-2FBF43E173D7Q37288434-62A71351-AD39-40FE-B446-63625022C8BCQ37469500-21395595-4ADF-43DD-9368-C693B786FF95Q37507509-5110194B-6678-41E0-AAB9-D6BB0BF5ADEFQ37695051-4C9A4688-C057-4FCA-AC96-BE5ED1A7D0C9Q37780706-FAFFF182-4456-48EC-BC97-9C4B68353AC3Q38029093-4C895997-EF27-4C86-AF5E-252ED31A3FFCQ38984209-23A19DC1-9B78-4869-8CA9-CCDAE24626BFQ39002759-CF8828DF-29C5-4040-BFA8-F5C65FDC08AEQ39003177-9EEBCB6A-04E3-4073-8058-A0D234A16E28Q39281253-DB612E34-DE5A-4239-9E98-008C0906E818Q39455597-BBB4B729-9840-4D2A-8533-F708CA94E9B3Q39643842-C9E6B2FE-68EE-49D6-B5C5-FED8E91E2804Q40250347-86504258-047D-4274-953A-D207CFFF572EQ40284342-53F9E5C9-C992-4EE1-8606-E0F6C982B2E0Q40327792-8FC4BB3D-E399-4E55-BBE9-35F9659B1335Q40628228-3A0E1F56-E1B5-4E66-916B-BC1E11B7E618Q40883096-88B55A43-8047-4B8D-8D9E-1CE0766EACF8Q41727813-F0355B58-BF28-45A7-B071-5E615F8F3D49Q41936053-33A13159-28F3-463D-B8BF-0AA63D1A1C05Q42235915-ECF90377-3125-4374-9B0F-9E42D15516E8
P2860
Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Cumulative HIV viremia during ...... ctor of AIDS-related lymphoma.
@en
Cumulative HIV viremia during ...... ctor of AIDS-related lymphoma.
@nl
type
label
Cumulative HIV viremia during ...... ctor of AIDS-related lymphoma.
@en
Cumulative HIV viremia during ...... ctor of AIDS-related lymphoma.
@nl
prefLabel
Cumulative HIV viremia during ...... ctor of AIDS-related lymphoma.
@en
Cumulative HIV viremia during ...... ctor of AIDS-related lymphoma.
@nl
P2093
P50
P921
P356
P1476
Cumulative HIV viremia during ...... ctor of AIDS-related lymphoma.
@en
P2093
Alexander Zoufaly
Christian Hoffmann
Christian Kollan
ClinSurv Study Group
Hans-Jürgen Stellbrink
Matthias An der Heiden
Osamah Hamouda
P356
10.1086/599313
P407
P577
2009-07-01T00:00:00Z